Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by Calamos Advisors LLC

Calamos Advisors LLC boosted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 10.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 326,629 shares of the medical equipment provider’s stock after purchasing an additional 30,908 shares during the quarter. Calamos Advisors LLC owned approximately 0.16% of Zimmer Biomet worth $39,751,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in shares of Zimmer Biomet by 19.0% during the first quarter. Vanguard Group Inc. now owns 23,102,761 shares of the medical equipment provider’s stock valued at $2,954,843,000 after purchasing an additional 3,695,510 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Zimmer Biomet by 21.2% during the third quarter. American Century Companies Inc. now owns 4,863,741 shares of the medical equipment provider’s stock valued at $545,809,000 after purchasing an additional 852,186 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Zimmer Biomet by 2.3% during the first quarter. Geode Capital Management LLC now owns 4,315,167 shares of the medical equipment provider’s stock valued at $556,244,000 after purchasing an additional 96,028 shares during the last quarter. Morgan Stanley lifted its holdings in shares of Zimmer Biomet by 80.5% during the fourth quarter. Morgan Stanley now owns 3,102,429 shares of the medical equipment provider’s stock valued at $395,560,000 after purchasing an additional 1,384,068 shares during the last quarter. Finally, Victory Capital Management Inc. raised its position in Zimmer Biomet by 4.9% during the third quarter. Victory Capital Management Inc. now owns 3,080,463 shares of the medical equipment provider’s stock valued at $345,690,000 after buying an additional 144,147 shares during the period. 88.89% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the company. Barclays upped their price target on Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research report on Monday, February 12th. JPMorgan Chase & Co. upped their price target on Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. Evercore ISI upped their target price on Zimmer Biomet from $125.00 to $130.00 and gave the stock an “in-line” rating in a research report on Thursday, April 4th. Raymond James upped their target price on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. Finally, StockNews.com lowered Zimmer Biomet from a “strong-buy” rating to a “buy” rating in a research report on Monday, February 19th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and an average target price of $139.39.

Insider Activity at Zimmer Biomet

In other news, VP Chad F. Phipps sold 26,156 shares of Zimmer Biomet stock in a transaction on Thursday, February 22nd. The shares were sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the completion of the sale, the vice president now directly owns 44,145 shares of the company’s stock, valued at approximately $5,677,929.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.95% of the stock is owned by company insiders.

Zimmer Biomet Trading Down 1.6 %

ZBH traded down $1.97 during trading on Thursday, reaching $119.33. 1,442,170 shares of the stock traded hands, compared to its average volume of 1,483,552. The company has a quick ratio of 0.78, a current ratio of 1.61 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $24.52 billion, a PE ratio of 24.81, a P/E/G ratio of 2.24 and a beta of 1.01. The stock’s 50-day moving average is $126.47 and its 200 day moving average is $119.10. Zimmer Biomet Holdings, Inc. has a 12 month low of $102.00 and a 12 month high of $149.25.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, beating the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a net margin of 13.85% and a return on equity of 12.79%. The business had revenue of $1.94 billion for the quarter, compared to analysts’ expectations of $1.93 billion. During the same quarter last year, the firm earned $1.88 EPS. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. Equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be paid a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, March 27th. This represents a $0.96 dividend on an annualized basis and a yield of 0.80%. Zimmer Biomet’s dividend payout ratio is 19.63%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.